Nociception Evaluated by the NOL® Index in Sedated Patients in the Intensive Care Unit

July 17, 2023 updated by: Antonello Penna, University of Chile

Due to their underlying pathology and the necessary complicated procedures to which they are exposed, patients in the intensive care unit experience varying degrees of pain at some point in their evolution. Evidence has established short-term and long-term negative consequences of unresolved pain or excessive analgesic sedation. However, pain assessment or adequate nociceptive monitoring remains a significant challenge, especially in non-communicative patients under deep sedation, who urgently need to expand and improve current tools.

Pain assessment in critically ill patients is challenging; limitations in their ability to communicate (neurocognitive deficit, use of endotracheal tube) or altered consciousness (deep sedation) make them unable to self-report their pain with standard pain scales. The Behavioral Pain Scale (BPS) and the Critical-Care Pain Observation Tool (CPOT) are the pain assessment tools with the best performance and reliability for patients in these conditions.

Different technologies are used to monitor nociceptive responses caused by surgical stress in patients under general anesthesia that together with the clinical evaluation, manage to keep patients in the best analgesic conditions, improving the post-surgical prognosis. In particular, the NOL® nociceptive index (Medasense, Ramat Gan, Israel) is a multiparametric detection of nociception/pain, delivering a dimensionless score (0 -100) calculated through an algorithm (patented) and based on the registry of four biometric sensors (photoplethysmography, galvanic skin response, temperature, and accelerometer). NOL index value between 10-25 is the most appropriate for maintaining analgesia during general anesthesia.

The ease and low invasiveness of this system (all sensors are implemented in a finger clip, similar to an oxygen saturation monitor) may allow its potential use in the context of intensive care unit patients. Some studies have recently been published that highlight the possible usefulness of the NOL® index in critically ill patients. However, in these studies, the assessment of nociception was limited to acute nociceptive procedures only.

Study Overview

Status

Suspended

Intervention / Treatment

Detailed Description

In the following protocol, we will study the feasibility of using the NOL® index to evaluate nociception in patients under sedation with propofol and opioid analgesics such as fentanyl.

This study aims to describe the feasibility of using the NOL® nociception index as an objective tool for assessing pain/nociception in patients with sedation in the Intensive Care Unit (ICU).

The values obtained with the use of the NOL® index will be recorded and compared with the standard measurements of pain assessment (Behavioral Pain Scale (BPS) and/or Critical-Care Pain Observation Tool (CPOT)) in patients with a deep/superficial sedation protocol (SAS 1-2). The values obtained after exposure to nociceptive stimuli such as interventions, cleaning, and invasive procedures, among others, will be registered.

In particular, scales such as CPOT and NOL® can be complementary since both measure different components related to pain. The CPOT measures expressive behaviors related to pain, and the NOL measures physiological parameters involved in the process of nociception, which can lead to pain.

Two other aims:

To compare the registration of the NOL® index and the degree of sedation by the BIS® index with variables derived from the processing of the frontal EEG.

To evaluate the effect of sedo-analgesia protocols on the NOL® index. The impact of administering sedation/analgesia protocols with propofol/fentanyl and their effects on the NOL® index will be followed up and evaluated.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • RM
      • Santiago, RM, Chile, 7690306
        • Centro de Investigación Cínica Avanzada (CICA), Hospital Clinico de la Universidad de Chile
      • Santiago, RM, Chile, 7690306
        • Hospital Clinico de la Universidad de Chile

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

ICU patients sedated with propofol and fentanyl

Description

Inclusion Criteria:

  • ICU sedated patients under propofol and fentanyl

Exclusion Criteria:

  • Sedation duration less than 72 h
  • Stroke
  • Opioid user before ICU hospitalization
  • Atrial fibrillation
  • Pregnancy/lactation
  • Patient with antiarrhythmic agents

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ICU sedated patients
Critical patients sedated with propofol and fentanyl The values obtained with the use of the NOL® index will be recorded and compared with the standard measurements of pain assessment (Behavioral Pain Scale (BPS) and/or CPOT)
NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NOL monitor values
Time Frame: Day 3
Values will be recorded and compared with fentanyl dosage and clinical pain assesment
Day 3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fentanyl dosage
Time Frame: Day 3
Values of fentanyl dosage
Day 3
Clinical pain assessment (Behavioral Pain Scale)
Time Frame: Day 3
Values of pain scale
Day 3
BIS index
Time Frame: Day 3
Values of BIS index obtained by BIS monitor
Day 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2022

Primary Completion (Actual)

January 31, 2023

Study Completion (Estimated)

July 20, 2023

Study Registration Dates

First Submitted

May 16, 2022

First Submitted That Met QC Criteria

May 30, 2022

First Posted (Actual)

June 1, 2022

Study Record Updates

Last Update Posted (Actual)

July 19, 2023

Last Update Submitted That Met QC Criteria

July 17, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OAIC: 1219/21

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sedation Complication

Clinical Trials on NOL monitor

Subscribe